Related Experiment Video

Updated: Oct 4, 2026

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
14:39

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

Is there a relationship between plasma phenylalanine and cholesterol in phenylketonuric patients under dietary

C Colomé1, R Artuch, N Lambruschini

  • 1Servei de Bioquímica, Servei de Pediatria i Neuropediatria, Unitat Integrada, Hospital Sant Joan de Déu/Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.

Clinical Biochemistry
|August 28, 2001
PubMed

Insights

Treated phenylketonuria (PKU) patients exhibit lower cholesterol levels compared to other metabolic disorder groups. High phenylalanine may inhibit cholesterol production, though diet also plays a role.

Area of Science:

  • Biochemistry
  • Metabolic Disorders
  • Clinical Nutrition

Background:

  • Phenylketonuria (PKU) is a genetic disorder requiring strict dietary management.
  • Altered lipid profiles are observed in various metabolic conditions.
  • Understanding lipid metabolism in PKU is crucial for comprehensive patient care.

Purpose of the Study:

  • To compare lipid profiles, specifically cholesterol and triglycerides, in treated PKU patients.
  • To investigate the relationship between phenylalanine levels and lipid metabolism.
  • To differentiate lipid profiles between PKU, hyperphenylalaninemia (HPA), and other inborn errors of metabolism (IEM).

Main Methods:

  • Analysis of serum phenylalanine using ion exchange chromatography.
  • Determination of triglycerides, cholesterol, and HDL using standard analyzer procedures.
  • Comparative analysis across four groups: treated PKU, IEM, HPA, and healthy controls.

Main Results:

  • PKU patients showed significantly lower serum total cholesterol compared to IEM, HPA, and control groups.
  • A negative correlation was found between plasma phenylalanine and cholesterol concentrations in PKU patients.
  • Cholesterol intake was similar between PKU and IEM groups, suggesting a metabolic effect.

Conclusions:

  • Findings support a link between elevated phenylalanine and reduced cholesterogenesis in PKU.
  • Dietary cholesterol intake from special PKU diets may also contribute to lower serum cholesterol.
  • Further research is warranted to elucidate the precise mechanisms of lipid dysregulation in PKU.
Abstract

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...